Chris leads the CMC statistics group for biologics development at AstraZeneca. He has spent the last 20 years working in CMC both in the lab and as a statistician. His recent focus has been how statistics can leverage platform knowledge to improve decision making. In addition to IABS, Chris is also involved with the IQ consortium and co-chairs the workgroup for Bayesian statistics in CMC for the ASA.